A novel target to turn cold tumors into hot tumors: lysosomal 25-hydroxycholesterol activates AMPKα and immunosuppressive tumor-associated macrophages  

作　　者：Shuangshuang Liu Jiaqi Wu Xiao Tong Li-Hao Huang 

机构地区：[1]Shanghai Key Laboratory of Metabolic Remodeling and Health,Institute of Metabolism and Integrative Biology,Zhongshan Hospital,Fudan University,Shanghai,200032,China

出　　处：《Cellular & Molecular Immunology》2024年第8期801-803,共3页中国免疫学杂志（英文版）

基　　金：National Natural Science Foundation of China(Project:32371243,32171168,32350610248).

摘　　要：In a recent issue of Immunity,Xiao et al.reported that cholesterol 25-hydroxylase(CH25H)is a novel immunometabolic checkpoint and a potential drug target for tumor immunotherapy[1].Their study elucidated how CH25H influences macrophage polarization and reshapes the tumor microenvironment(TME)by regulating the lysosomal 25-hydroxycholesterol(25HC)content and AMPKa activation(Fig.1).Fehleisen and Busch,two physicians from Germany,independently observed significant tumor regression following erysipelas infection in the late 19th century,and they provided the earliest scientific evidence for tumor immunotherapy[2].To date,immunotherapy has emerged as a focal point in cancer treatment,with the concept of the TME pivotal for understanding cancer initiation and progression[3].

关 键 词：CHOLESTEROL al. cancer 

分 类 号：R392[医药卫生—免疫学]